Deep Genomics
Deep Genomics is an AI-driven genetic medicines company that uses proprietary foundation models (BigRNA, REPRESS, DeepADAR) on its BioFM Platform to discover and design RNA-based therapeutics for rare genetic diseases, partnering with pharmaceutical companies like BioMarin and Wave Life Sciences for development and commercialization.
- Company typePrivate
- Founded2015
- HeadquartersToronto, Canada
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Deep Genomics does
Deep Genomics Incorporated is an AI-driven genetic medicines company founded in 2015 by University of Toronto professor Brendan Frey, headquartered in Toronto with a clinical and business development office in Cambridge, Massachusetts. The company operates the BioFM (Biological Foundation Model) Platform, an integrated discovery engine that combines lab-in-the-loop workflows, proprietary training datasets, AI model development, screening technologies, and software systems. On this common architecture Deep Genomics builds, runs, and improves a stack of proprietary foundation models — most notably BigRNA (nearly 2 billion tunable parameters trained on over one trillion genomic signals, predicting tissue-specific RNA expression, splicing, protein/microRNA binding, and designing steric-blocking oligonucleotides), REPRESS (predicting microRNA binding and mRNA degradation from sequence), and DeepADAR (designing guide RNAs for ADAR-mediated RNA editing). The platform has reported a 70% research-to-therapeutic-lead success rate and target-to-drug-candidate timelines under 12 months, materially shorter than industry-standard drug discovery cycles.
Deep Genomics is organized as an enterprise B2B TechBio that monetizes through strategic partnerships with pharmaceutical and biotechnology companies rather than through direct product sales. Revenue mechanics consist of upfront payments, development and regulatory milestones, and potential royalties on programs the company out-licenses. Named enterprise partners include BioMarin Pharmaceutical (a preclinical collaboration across four rare-disease indications announced in November 2020) and Wave Life Sciences (a neuromuscular splicing collaboration announced in April 2018). The company is advancing 10+ preclinical programs — with the Series C use of funds targeting 30 programs and four clinical entries by 2023 — focused on rare genetic diseases such as Wilson disease and neuromuscular disorders. The internal pipeline runs in parallel with partner-funded programs, allowing Deep Genomics to capture long-tail upside from any programs it advances independently.
Deep Genomics has raised approximately $236.4 million across multiple rounds from SoftBank Vision Fund 2, CPP Investments, Fidelity, Khosla Ventures, True Ventures, Future Ventures, and Amplitude Ventures. Leadership has evolved from a founder-led research organization into a commercially oriented company: founder Brendan Frey moved to Chief Innovation Officer in September 2023 when biotech operator Brian O'Callaghan was appointed CEO, with subsequent additions of a CTO (Radu Dobrin), CSO (Greg Hoffman), VP Machine Learning (Joel Shor), and CBO (Clive Bertram) in 2024. The company has been recognized with the 2024 Stevie Award for BioTechnology Company of the Year and a 2025 Gold Stevie Award for Biotech Executive of the Year (O'Callaghan).
Deep Genomics firmographics
Firmographics- Name
- Deep Genomics
- Legal name
- Deep Genomics Incorporated
- Website
- https://deepgenomics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Deep Genomics is an AI-driven genetic medicines company that uses proprietary foundation models (BigRNA, REPRESS, DeepADAR) on its BioFM Platform to discover and design RNA-based therapeutics for rare genetic diseases, partnering with pharmaceutical companies like BioMarin and Wave Life Sciences for development and commercialization.
- Ownership category
- akta.pro rank
Deep Genomics industry classification
Industry- Product category
- AI-driven drug discovery platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Deep Genomics is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Deep Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Partnership and Collaboration Revenue: Deep Genomics generates revenue through strategic partnerships with pharmaceutical companies. They receive upfront payments and are eligible for development milestones as programs advance through preclinical and clinical stages. Partners like BioMarin receive exclusive options to obtain rights to programs for development and commercialization.
- Pipeline Development and Licensing: The company develops proprietary therapeutic candidates through its AI platform and plans to advance programs into the clinic, potentially licensing out or partnering at various stages of development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Deep Genomics product offering
Product offeringCore offering
Deep Genomics operates an AI-driven genetic medicines platform (the BioFM Platform) that uses proprietary biological foundation models—including BigRNA, REPRESS, and DeepADAR—to predict RNA biology mechanisms and design oligonucleotide-based therapeutic candidates for rare genetic diseases. The company partners with pharmaceutical companies like BioMarin and Wave Life Sciences to advance these candidates through clinical development and commercialization in exchange for upfront payments, milestones, and royalties.
Product overview
Deep Genomics operates as an AI-first TechBio organization offering a unified platform called the BioFM (Biological Foundation Model) Platform. The platform comprises multiple AI foundation models including BigRNA (the core RNA biology decoder and therapeutic designer), REPRESS (for microRNA binding and mRNA degradation prediction), and DeepADAR (for ADAR-mediated RNA editing design). These models work in concert within a lab-in-the-loop workflow system, combining computational AI predictions with experimental validation to discover disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- BioFM Platform Comprehensive AI-driven genetic medicines platform that combines lab-in-the-loop workflows, AI model development, fit-for-purpose training datasets, screening technologies, and software systems to build, run, and improve Biological Foundation Models for drug discovery; used by Deep Genomics internally and made available to pharmaceutical partners to identify disease mechanisms and design RNA-based therapeutic candidates for genetic diseases.
- BigRNA First AI foundation model for RNA therapeutics, with nearly 2 billion tunable parameters trained on over one trillion genomic signals; predicts tissue-specific RNA expression, splicing, microRNA binding, and designs steric blocking oligonucleotides as therapeutic candidates, outperforming state-of-the-art methods in 152 of 153 protein and microRNA binding site predictions.
- REPRESS Deep learning foundation model that predicts cell-type-specific microRNA (miRNA) binding and mRNA degradation directly from RNA sequences, revealing regulatory mechanisms missed by other state-of-the-art methods and outperforming seven leading methods across seven benchmarks; part of the BioFM Platform.
- DeepADAR AI foundation model that designs guide RNAs (gRNAs) to induce ADAR-mediated editing across various trinucleotide contexts, predicting endogenous and gRNA-driven editing based on local sequence and structural features for RNA editing therapeutics.
Quantifiable outcome
- 70% of research projects led to therapeutic leads
- +3 more outcomes
Companies that use Deep Genomics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Deep Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature5 records
Deep Genomics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Mila (Quebec Artificial Intelligence Institute)minorDeep Genomics joined Mila's community to access recruitment activities and collaborate with AI researchers. Partnership supports talent acquisition and long-term AI collaboration with Professor Yoshua Bengio's institute.
- BioMarin Pharmaceutical Inc.corePreclinical collaboration using Deep Genomics' AI Workbench to identify oligonucleotide drug candidates in four rare disease indications. Deep Genomics receives undisclosed upfront payment and eligible for development milestones. BioMarin receives exclusive option to obtain rights to each program for development and commercialization.
- Wave Life SciencescoreCollaboration to discover novel therapies for genetic neuromuscular disorders. Deep Genomics uses machine learning platform to identify cause and effect relationships for splicing regulation targets; Wave uses proprietary chemistry platform to validate targets and elucidate implications across different phenotypes.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
Deep Genomics competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-first drug discovery company combining high-throughput biology with foundation models to identify therapeutic candidates; most directly comparable to Deep Genomics on platform-centric, AI-driven discovery and pharma partnership model.
- Insitro: Machine learning-driven drug discovery platform using large-scale data generation and predictive models; comparable to Deep Genomics in combining proprietary ML with lab experimentation and in targeting genetic and metabolic diseases.
- Generate:Biomedicines: Generative AI platform for designing novel protein therapeutics; closest direct peer on foundation-model architecture for biology and partnership-driven commercialization with pharma.
- Isomorphic Labs: Alphabet-backed AI drug discovery company building foundation models for biology; competes for the same enterprise pharma partnership channel and shared talent pool as Deep Genomics.
- Exscientia: AI-driven precision medicine company with partnered and internal pipeline; comparable in business model (pharma partnerships, platform-as-product) and AI-led small-molecule/biologic discovery.
- XtalPi: AI- and quantum physics-driven drug discovery platform with partnerships across global pharma; comparable in scale, enterprise sales motion, and platform-as-engine approach to molecular design.
Broad incumbents
- Schrödinger: Computational chemistry and predictive modeling platform serving pharma R&D; broader portfolio of tools and customers but overlaps significantly with Deep Genomics on AI-enabled molecular design and enterprise pharma go-to-market.
- Ionis Pharmaceuticals: Established antisense oligonucleotide therapeutics leader with broad pipeline and partnerships; sets the bar for RNA-targeted genetic medicines and competes with Deep Genomics' oligonucleotide design approach at the modality level.
Emerging players
- Wave Life Sciences: Clinical-stage RNA therapeutics company with proprietary chemistry platform; simultaneously a strategic partner of Deep Genomics and a modality peer — both design nucleic-acid therapeutics for genetic diseases.
- Stoke Therapeutics: RNA-based medicine company using antisense oligonucleotides for genetic diseases; targets similar rare-disease indications as Deep Genomics and competes for partnership and licensing opportunities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Deep Genomics social profiles
Digital presenceDeep Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deep Genomics leadership team
Management profileNumber of profiles
Profiles17 records
Deep Genomics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deep Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deep Genomics
What does Deep Genomics do?
Deep Genomics operates an AI-driven genetic medicines platform (the BioFM Platform) that uses proprietary biological foundation models—including BigRNA, REPRESS, and DeepADAR—to predict RNA biology mechanisms and design oligonucleotide-based therapeutic candidates for rare genetic diseases. The company partners with pharmaceutical companies like BioMarin and Wave Life Sciences to advance these candidates through clinical development and commercialization in exchange for upfront payments, milestones, and royalties.
Is Deep Genomics a public or private company?
Deep Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Deep Genomics founded?
Deep Genomics was founded in 2015. It employs 101 to 250 people.
Where is Deep Genomics based?
Deep Genomics is headquartered in Toronto, Canada, in the North America region.
How does Deep Genomics make money?
Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are pipeline Development and Licensing.
Who are Deep Genomics's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Generate:Biomedicines, Isomorphic Labs, Exscientia and XtalPi. Broad incumbents are Schrödinger and Ionis Pharmaceuticals. Emerging players are Wave Life Sciences and Stoke Therapeutics.
Does Deep Genomics have an API?
No public API is recorded for Deep Genomics.
What industry is Deep Genomics in?
Deep Genomics's product category is AI-driven drug discovery platform. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 8731.